Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Selvita, Felicitex Therapeutics deal

    Selvita S.A. (Warsaw:SLV), Krakow, Poland Felicitex Therapeutics Inc., Cambridge, Mass. Business: Cancer The companies partnered to develop breakthrough personalized small molecule therapeutics targeting proteins within…

    Published on 12/15/2014
  • Sevion Therapeutics, Avidity deal

    Sevion Therapeutics Inc. (OTCQB:SVON), Bridgewater, N.J. Avidity NanoMedicines LLC, La Jolla, Calif. Business: Pharmaceuticals The companies partnered to use Sevions chimerasome technology to deliver nucleic acids. …

    Published on 12/15/2014
  • Shire, Cystic Fibrosis Foundation deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Cystic Fibrosis Foundation, Bethesda, Md. Business: Pulmonary Shire partnered with the foundations drug discovery and development arm, Cystic Fibrosis Foundation …

    Published on 12/15/2014
  • Spark Therapeutics, Pfizer deal

    Spark Therapeutics LLC, Philadelphia, Pa. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Hematology The companies partnered to develop and commercialize Sparks SPK-FIX program to treat hemophilia Beta. The …

    Published on 12/15/2014
  • Trimel Pharmaceuticals, Endo deal

    Trimel Pharmaceuticals Corp. (TSX:TRL), Mississauga, Ontario Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Endocrine/Metabolic Trimel granted Endo exclusive rights to commercialize Natesto in …

    Published on 12/15/2014
  • Vaccinex, J&J deal

    Vaccinex Inc., Rochester, N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Vaccinex partnered with Johnson & Johnsons Janssen Research & Development LLC unit to discover and develop human mAbs to …

    Published on 12/15/2014
  • Abbott, Mylan deal

    Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Generics The companies amended a July deal under which Mylan is acquiring Abbotts ex-U.S. developed markets branded …

    Published on 12/8/2014
  • Academy of Military Medical Sciences, Sihuan deal

    The Academy of Military Medical Sciences, Beijing, China Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460), Haikou, China Business: Infectious The Institute of Microbiology and Epidemiology of the academy sold jk-05…

    Published on 12/8/2014
  • Addex, Charcot-Marie-Tooth Association deal

    Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland The Charcot-Marie-Tooth Association (CMTA), Glenolden, Pa. Business: Neurology The association will evaluate Addexs ADZ71441 in preclinical models of Charcot-Marie…

    Published on 12/8/2014
  • Aesica Pharmaceuticals, Consort Medical deal

    Aesica Pharmaceuticals Ltd., Newcastle upon Tyne, U.K. Consort Medical plc (LSE:CSRT), Hemel Hempstead, U.K. Business: Supply/Service Consort acquired Aesica for 230 million ($360 million). Aesica is a contract …

    Published on 12/8/2014
  • Array BioPharma, Novartis deal

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer The companies will terminate a 2010 deal granting Novartis exclusive, worldwide rights to oncology …

    Published on 12/8/2014
  • Astellas, J&J deal

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Johnson & Johnsons Janssen Biotech Inc. subsidiary exercised its right to terminate a 2012 deal with…

    Published on 12/8/2014
  • AstraZeneca, University of Cambridge deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. University of Cambridge, Cambridge, U.K. Business: Neurology Under a three-year deal, AstraZeneca, its MedImmune LLC biologics unit and the university partnered to …

    Published on 12/8/2014
  • Avanir, Otsuka Pharmaceutical deal

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Neurology Otsuka is acquiring Avanir for $17 per share in a deal valued at about $3.5 billion. The …

    Published on 12/8/2014
  • Boehringer Ingelheim, WellPoint deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany WellPoint Inc. (NYSE:WLP), Indianapolis, Ind. Business: Cardiovascular Boehringer and WellPoints HealthCore Inc. unit have identified non-valvular atrial fibrillation (NVAF)…

    Published on 12/8/2014
  • Broad Institute, Editas Medicine deal

    Broad Institute of MIT and Harvard, Cambridge, Mass. Editas Medicine, Cambridge, Mass. Business: Functional genomics Editas received exclusive, worldwide rights to Broad Institutes IP related to CRISPR/Cas9 gene editing…

    Published on 12/8/2014
  • California Institute of Technology, ImmunoCellular deal

    California Institute of Technology, Pasadena, Calif. ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC), Calabasas, Calif. Business: Cancer The institute granted ImmunoCellular exclusive rights to develop antigen-specific T…

    Published on 12/8/2014
  • Camurus, Braeburn deal

    Camurus AB, Lund, Sweden Braeburn Pharmaceuticals S.p.r.l., Princeton, N.J. Business: Neurology Camurus granted Braeburn exclusive, North American rights to buprenorphine injection depot (CAM2038) to treat opioid …

    Published on 12/8/2014
  • Cancer Genetics, Beth Israel Deaconess deal

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Beth Israel Deaconess Medical Center, Boston, Mass. Business: Diagnostic Cancer Genetics and the center partnered to identify prognostic genomic biomarkers in …

    Published on 12/8/2014
  • CFR Pharmaceuticals, Abbott deal

    CFR Pharmaceuticals S.A., Santiago, Chile Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Generics Abbott completed its acquisition of generics specialty company CFR for about $2.9 billion in cash (see …

    Published on 12/8/2014
  • Eli Lilly, Boehringer Ingelheim deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Endocrine/Metabolic Boehringer and Eli Lilly amended a 2011 deal to co-develop and co-commercialize a portfolio of…

    Published on 12/8/2014
  • Enigma Diagnostics, Beijing Leadman Biochemistry deal

    Enigma Diagnostics Ltd., Salisbury, U.K. Beijing Leadman Biochemistry Co. Ltd. (SZSE:300289), Beijing, China Business: Diagnostic Enigma and Beijing Leadman formed a JV to provide Enigmas Enigma Mini Laboratory (Enigma …

    Published on 12/8/2014
  • Evotec, Deutsches Rheuma-Forschungszentrum, University Medical Center Hamburg-Eppendorf deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Deutsches Rheuma-Forschungszentrum, Berlin, Germany University Medical Center Hamburg-Eppendorf, Hamburg, Germany Business: Autoimmune Evotec partnered with Deutsches Rheuma-…

    Published on 12/8/2014
  • Five Prime, Bristol-Myers deal

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer The partners will jointly evaluate a combination of Bristol-Myers Opdivo …

    Published on 12/8/2014
  • GeNeuro, Servier deal

    GeNeuro S.A., Geneva, Switzerland Servier, Neuilly-sur-Seine, France Business: Autoimmune GeNeuro granted Servier an option to license exclusive rights to develop and commercialize GNbAC1 worldwide, excluding the U.S. …

    Published on 12/8/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993